TL;DR: Entelexo Biotherapeutics is a Y Combinator Winter 2021 startup Creating a New Class of Drugs to Address Incurable Autoimmune Diseases, currently active with a team of 3.
Creating a New Class of Drugs to Address Incurable Autoimmune Diseases
Last verified:
Entelexo is creating modern treatments for immune-mediated diseases, such as psoriasis, using novel engineered exosome technology.
Built by LemStudio
Yes. Entelexo Biotherapeutics was funded by Y Combinator in the Winter 2021 batch. Creating a New Class of Drugs to Address Incurable Autoimmune Diseases
Entelexo is creating modern treatments for immune-mediated diseases, such as psoriasis, using novel engineered exosome technology.
Entelexo Biotherapeutics was part of Y Combinator's Winter 2021 batch.
Entelexo Biotherapeutics has a team of 3 people according to Y Combinator's directory.
Entelexo Biotherapeutics is currently listed as Active with a team of 3 in Y Combinator's directory.
Loading interactive view…